# Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026
Canonical URL: https://biopharmsignal.com/news/CHRS/coherus-oncology-to-report-first-quarter-2026-financial-results-on-may-11-2026
Ticker: CHRS
Company: Coherus BioSciences, Inc.
Source: Coherus BioSciences, Inc.
Published: 2026-05-04 13:30 EST
Original Source URL: https://investors.coherus.com
## Summary

REDWOOD CITY, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its first quarter 2026 financial results will be released after market close on Monday, May 11, 2026. Starting at 5:00 p.m. Eastern Time on May 11, 2026, Coherus’ management team will

## Article Body
REDWOOD CITY, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its first quarter 2026 financial results will be released after market close on Monday, May 11, 2026. Starting at 5:00 p.m. Eastern Time on May 11, 2026, Coherus’ management team will
## Recent Company News
- 2026-05-11 20:05 EST — [Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/CHRS/coherus-oncology-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Coherus BioSciences, Inc.
- 2026-05-04 13:30 EST — [Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026](https://biopharmsignal.com/news/CHRS/coherus-oncology-to-report-first-quarter-2026-financial-results-on-may-11-2026) — Source: Coherus BioSciences, Inc.
- 2026-03-09 20:15 EST — [Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update](https://biopharmsignal.com/news/CHRS/coherus-oncology-reports-full-year-and-fourth-quarter-2025-financial-results-and-provides-business-update) — Source: Coherus BioSciences, Inc.
- 2026-03-02 14:30 EST — [Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026](https://biopharmsignal.com/news/CHRS/coherus-oncology-to-report-full-year-and-fourth-quarter-2025-financial-results-on-march-9-2026) — Source: Coherus BioSciences, Inc.
- 2026-02-23 14:30 EST — [Coherus Oncology to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/CHRS/coherus-oncology-to-participate-in-upcoming-investor-conferences) — Source: Coherus BioSciences, Inc.
## Related News
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)
- 2026-07-22 20:01 EST — AXON — [Axon to Release Second Quarter 2026 Earnings on August 5, 2026](https://biopharmsignal.com/news/AXON/axon-to-release-second-quarter-2026-earnings-on-august-5-2026-66120902)
- 2026-07-22 12:39 EST — ARTL — [New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition](https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432)
- 2026-07-22 12:30 EST — NRSN — [NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS](https://biopharmsignal.com/news/NRSN/neurosense-advances-primec-toward-new-drug-submission-to-health-canada-for-als-721c198c)